This review paper focuses on prevention strategies and clinical management of methicillinresistant Staphylococcus aureus (MRSA) infections in ventilated patients who developventilator-associated pneumonia (VAP). Since MRSA are the most frequently isolated bacteria in patients with VAP, and a significant cause of morbidity and mortality in intubated patients, rapiddiagnosis and early treatment could reduce mortality. By taking a few preventive steps (i.e. screening ventilated patients for MRSA, decolonization, and handwashing), MRSA-associatedVAP can be effectively controlled. Clinical presentations can be used before the results of culture are obtained to direct empiric treatment, but upon culture confirmation of MRSA, the useof an appropriate antibiotic therapy earlier on could help in the management of VAP. Vancomycin or linezolid are the current drugs of choice for MRSA-associated VAP, while new drugs and monoclonal antibodies are in clinical trials.
【 预 览 】
附件列表
Files
Size
Format
View
Management of methicillin-resistant Staphylococcus aureus mediated ventilatorassociated pneumonia